Comgest Global Investors S.A.S. Bio N Tech Se Transaction History

Comgest Global Investors S.A.S.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$98.5 - $125.08 $1.96 Million - $2.48 Million	-19,862 Reduced 9.57%	187,746 $20.4 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $1.87 Million - $2.34 Million	-15,244 Reduced 6.84%	207,608 $25.9 Million
Q4 2022 May 15, 2023	SELL	$118.43 - $186.05 $421,966 - $662,896	-3,563 Reduced 1.57%	222,852 $33.5 Million
Q4 2022 Feb 10, 2023	SELL	$118.43 - $186.05 $421,966 - $662,896	-3,563 Reduced 1.57%	222,852 $33.5 Million
Q3 2022 May 15, 2023	SELL	$127.65 - $183.11 $1.41 Million - $2.02 Million	-11,046 Reduced 4.65%	226,415 $30.5 Million
Q3 2022 Nov 10, 2022	SELL	$127.65 - $183.11 $1.41 Million - $2.02 Million	-11,046 Reduced 4.65%	226,415 $30.5 Million
Q2 2022 May 15, 2023	SELL	$123.25 - $186.24 $2.54 Million - $3.84 Million	-20,602 Reduced 7.98%	237,461 $35.4 Million
Q2 2022 Jul 28, 2022	SELL	$123.25 - $186.24 $2.54 Million - $3.84 Million	-20,602 Reduced 7.98%	237,461 $35.4 Million
Q1 2022 May 15, 2023	BUY	$126.25 - $231.85 $6.37 Million - $11.7 Million	50,455 Added 24.3%	258,063 $44 Million
Q1 2022 May 13, 2022	BUY	$126.25 - $231.85 $8.68 Million - $15.9 Million	68,788 Added 36.34%	258,063 $44 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $1.55 Million - $2.6 Million	7,177 Added 3.94%	189,275 $48.8 Million
Q3 2021 Nov 02, 2021	SELL	$205.93 - $447.23 $22 Million - $47.8 Million	-106,881 Reduced 36.99%	182,098 $49.7 Million
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $32.7 Million - $69.8 Million	288,979 New	288,979 $64.7 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Comgest Global Investors S.A.S., based on Form 13F filings with the SEC.

Stay updated on Comgest Global Investors S.A.S. with notifications on news.